La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Intensity Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Intensity Therapeutics..

Intensity Therapeutics (NASDAQ:INTS) Azioni, Catena delle Opzioni

INTENSITY THERAPEUTICS INC

Intensity Therapeutics

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics Inc

Earnings

Earnings Beats

News

TALO

Talos Energy Q1 Adj. EPS $(0.06) Beats $(0.09) Estimate, Sales $513.06M Beat $498.89M Estimate

Ingevity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) widens FY2025 sales outlook from $1.30 billion-$1.40 billion to $1.25 billion-$1.40 billion vs $1.36 billion estimate.

Guidance

NGVT

Ingevity Widens FY2025 Sales Guidance from $1.30B-$1.40B to $1.25B-$1.40B vs $1.36B Est

Playa Hotels &amp; Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLYA#NASDAQ">PLYA</a>) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.36 by 2.78 percent. This is a 7.5 percent decrease over earnings of $0.40 per share from the same period last year. The company reported quarterly sales of $267.29 million which beat the analyst consensus estimate of $266.84 million by 0.17 percent. This is a 11.09 percent decrease over sales of $300.63 million the same period last year.

PLYA

Playa Hotels & Resorts Q1 Adj. EPS $0.37 Beats $0.36 Estimate, Sales $267.29M Beat $266.84M Estimate

Atlas Energy Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AESI#NYSE">AESI</a>) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.16 by 93.75 percent. This is a 96.15 percent decrease over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $297.59 million which beat the analyst consensus estimate of $290.07 million by 2.59 percent. This is a 54.46 percent increase over sales of $192.67 million the same period last year.

Earnings Misses

AESI

Atlas Energy Solutions Q1 EPS $0.01 Misses $0.16 Estimate, Sales $297.59M Beat $290.07M Estimate

New Mountain Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMFC#NASDAQ">NMFC</a>) reported quarterly earnings of $0.32 per share which met the analyst consensus estimate. This is a 11.11 percent decrease over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $85.66 million which missed the analyst consensus estimate of $86.65 million by 1.14 percent. This is a 5.40 percent decrease over sales of $90.56 million the same period last year.

NMFC

New Mountain Finance Q1 Net Investment Income $0.32, Inline, Sales $85.66M Miss $86.65M Estimate

Ingevity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) reported quarterly earnings of $0.99 per share which beat the analyst consensus estimate of $0.74 by 33.78 percent. This is a 90.38 percent increase over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $284.00 million which missed the analyst consensus estimate of $285.47 million by 0.51 percent. This is a 16.50 percent decrease over sales of $340.10 million the same period last year.

Ingevity Q1 Adj. EPS $0.99 Beats $0.74 Estimate, Sales $284.00M Miss $285.47M Estimate

Primoris Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRIM#NASDAQ">PRIM</a>) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.66 by 48.48 percent. This is a 108.51 percent increase over earnings of $0.47 per share from the same period last year. The company reported quarterly sales of $1.65 billion which beat the analyst consensus estimate of $1.49 billion by 10.58 percent. This is a 16.63 percent increase over sales of $1.41 billion the same period last year.

PRIM

Primoris Services Q1 Adj. EPS $0.98 Beats $0.66 Estimate, Sales $1.65B Beat $1.49B Estimate

Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) is looking for Q4 Adj EPS of $2.50-$2.70 vs $2.69 analyst estimate. sees sales of $860.000 million-$900.000 million vs $888.62 million analyst estimate.

Fabrinet Sees Q4 Adj EPS $2.50-$2.70 vs $2.69 Est; Sees Sales $860.000M-$900.000M vs $888.62M Est

Certara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) affirms FY2025 Adj EPS guidance from $0.42-$0.46 to $0.42-$0.46 vs $0.45 analyst estimate. Affirms FY2025 sales outlook from $415.00 million-$425.00 million to $415.00 million-$425.00 million vs $420.67 million estimate.

CERT

Certara Affirms FY2025 Adj EPS Guidance of $0.42-$0.46 vs $0.45 Est; Affirms FY2025 Sales Guidance of $415.00M-$425.00M vs $420.67M Est

Spruce Power Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPRU#NYSE">SPRU</a>) ("Spruce" or the "Company") today announced that Sarah Wells, Chief Financial Officer ("CFO"), has resigned, effective May 14, 2025, to pursue other opportunities. Spruce expects to appoint an interim CFO prior to Wells departing. The Company is undertaking a search to fill the CFO position on a permanent basis.

Management

Spruce Power Holding Corporation Class A Common Stock

SPRU

Spruce Power Holding CFO Sarah Wells Resigns, Effective May 14, 2025

Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) raises FY2025 GAAP EPS guidance from $5.52-$5.92 to $5.73-$6.13 vs $5.64 analyst estimate..

Clorox Raises FY2025 GAAP EPS Guidance from $5.52-$5.92 to $5.73-$6.13 vs $5.64 Est

Boise Cascade (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCC#NYSE">BCC</a>) reported quarterly earnings of $1.06 per share which missed the analyst consensus estimate of $1.28 by 17.19 percent. This is a 59.39 percent decrease over earnings of $2.61 per share from the same period last year. The company reported quarterly sales of $1.54 billion which beat the analyst consensus estimate of $1.52 billion by 1.29 percent. This is a 6.63 percent decrease over sales of $1.65 billion the same period last year.

Boise Cascade Q1 EPS $1.06 Misses $1.28 Estimate, Sales $1.54B Beat $1.52B Estimate

Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) affirms FY2025 Adj EPS guidance from $6.95-$7.35 to $6.95-$7.35 vs $7.12 analyst estimate. Narrows FY2025 sales outlook from $7.02 billion-$7.24 billion to $7.02 billion-$7.09 billion vs $7.10 billion estimate.

Clorox Affirms FY2025 Adj EPS Guidance of $6.95-$7.35 vs $7.12 Est; Narrows FY2025 Sales Guidance from $7.02B-$7.24B to $7.02B-$7.09B vs $7.10B Est

Certara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.11 by 27.27 percent. This is a 40 percent increase over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $106.00 million which beat the analyst consensus estimate of $104.88 million by 1.07 percent. This is a 9.67 percent increase over sales of $96.65 million the same period last year.

Certara Q1 Adj. EPS $0.14 Beats $0.11 Estimate, Sales $106.00M Beat $104.88M Estimate

Crawford &amp; Company Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRD#NYSE">CRD</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.20 by 5 percent. This is a 61.54 percent increase over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $323.34 million which beat the analyst consensus estimate of $321.00 million by 0.73 percent. This is a 3.28 percent increase over sales of $313.07 million the same period last year.

CRD/B

Crawford & Company Common Stock Q1 Adj. EPS $0.21 Beats $0.20 Estimate, Sales $323.34M Beat $321.00M Estimate

Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) reported quarterly earnings of $2.25 per share which missed the analyst consensus estimate of $2.49 by 9.64 percent. This is a 5.86 percent decrease over earnings of $2.39 per share from the same period last year. The company reported quarterly sales of $871.80 million which beat the analyst consensus estimate of $856.62 million by 1.77 percent. This is a 19.17 percent increase over sales of $731.53 million the same period last year.

Fabrinet Q3 Adj. EPS $2.25 Misses $2.49 Estimate, Sales $871.80M Beat $856.62M Estimate

Vornado Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNO#NYSE">VNO</a>) reported quarterly earnings of $0.63 per share which beat the analyst consensus estimate of $0.56 by 12.5 percent. This is a 14.55 percent increase over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $461.58 million which beat the analyst consensus estimate of $452.13 million by 2.09 percent. This is a 5.78 percent increase over sales of $436.38 million the same period last year.

Vornado Realty Q1 FFO $0.63 Beats $0.56 Estimate, Sales $461.58M Beat $452.13M Estimate

SiriusPoint (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPNT#NYSE">SPNT</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.26 by 88.46 percent. This is unchanged from the same period last year. The company reported quarterly sales of $727.30 million which beat the analyst consensus estimate of $692.00 million by 5.10 percent. This is a 6.10 percent increase over sales of $685.50 million the same period last year.

SPNT

SiriusPoint Q1 GAAP EPS $0.49 Beats $0.26 Estimate, Sales $727.30M Beat $692.00M Estimate

WIIM

UPWK

Upwork shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 adjusted EPS guidance.

Interparfums (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPAR#NASDAQ">IPAR</a>) affirms FY2025 GAAP EPS guidance from $5.35 to $5.35 vs $5.34 analyst estimate. Affirms FY2025 sales outlook from $1.51 billion to $1.51 billion vs $1.51 billion estimate.

IPAR

Interparfums Affirms FY2025 GAAP EPS Guidance of $5.35 vs $5.34 Est; Affirms FY2025 Sales Guidance of $1.51B vs $1.51B Est

Press Releases

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Offerings

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

INTS

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Ainos

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

Aprea Therapeutics

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

HCW Biologics

iBio

Immuron Limited - American Depositary Shares

Immuron

MetaVia

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

PharmaCyte Biotech

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Turnstone Biologics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

Comments

Intensity Therapeutics

Intensity Therapeutics (INTS) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO